Phase II Study: Docetaxel Plus Oxaliplatin as Second-Line Therapy in Patients With Advanced Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Docetaxel (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms DocOx
- 02 Jun 2015 Final results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 18 Apr 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).